British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

The Kansas Supreme Court is weighing whether to block a sweeping state law that lets workers easily bypass COVID-19 vaccine ...